Creative Planning
BBNX

Creative Planning’s Beta Bionics BBNX Stock Holding History

Creative Planning’s Portfolio BBNX Stock Details BBNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$321K Buy
31,988
+25,290
+378% +$374K ﹤0.01% 3377
2025
Q4 		$204K Buy
+6,698
New +$179K ﹤0.01% 3537

Other funds holding BBNX

EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
SCV
Sands Capital Ventures Arlington, Virginia $421M AUM 26.25% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Creative Planning's BBNX Position: Q1 2026 in Review

Creative Planning increased its Beta Bionics (BBNX) stake by 378% in Q1 2026, buying an estimated $374K and bringing the position to 31,988 shares worth $321K. The position accounts for ﹤0.01% of the portfolio, ranked #3377.

Creative Planning first reported a position in BBNX in Q4 2025 and has held it in 2 quarters since. 130 funds tracked by Wall St. Rank hold BBNX as of Q1 2026.

  • Creative Planning held 31,988 shares of Beta Bionics worth $321K as of Q1 2026.
  • Creative Planning bought 25,290 Beta Bionics shares in Q1 2026, an estimated $374K.
  • Beta Bionics made up ﹤0.01% of Creative Planning's portfolio in Q1 2026, its #3377 holding.
  • Creative Planning first reported a position in Beta Bionics in Q4 2025 and has held it in 2 quarters since.
  • 130 funds tracked by Wall St. Rank held Beta Bionics as of Q1 2026.

Based on Creative Planning's 13F filing for Q1 2026, filed 12 May 2026.